D.E. Shaw & Co
CYT

D.E. Shaw & Co’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

D.E. Shaw & Co’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-58,529
Closed -$175K – 5637
2022
Q2 		$175K Sell
58,529
-13,330
-19% -$34K ﹤0.01% 4592
2022
Q1 		$271K Buy
71,859
+48,146
+203% +$274K ﹤0.01% 4709
2021
Q4 		$270K Buy
+23,713
New +$361K ﹤0.01% 4729

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co's CYT Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q3 2022, closing a stake of 58,529 shares — an estimated $175K sold.

D.E. Shaw & Co first reported a position in CYT in Q4 2021 and held it in 3 quarters. The position peaked at $271K in Q1 2022. 37 funds tracked by Wall St. Rank hold CYT as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 58,529 Cyteir Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $175K.
  • D.E. Shaw & Co first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • D.E. Shaw & Co's Cyteir Therapeutics, Inc. Common Stock position peaked at $271K in Q1 2022.
  • 37 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.